The global cancer therapy market is expected to register a CAGR of 6.5% during the forecast period, 2018 to 2023. North America dominates the market, due to growing prevalence of cancer diseases and rapid adoption of new therapy and novel drugs in the region.
Cancer is one of the leading causes of morbidity and mortality, globally. According to World Health Organization (WHO), in 2015, cancer was the second leading cause of death accounting for 8.8 million deaths, worldwide, and the number of new cancer cases is expected to rise by about 70% over the next two decades. It has been identified that approximately 70% of deaths from cancer occur in low- and middle-income countries. The growing incidence and prevalence of cancer and launch of novel cancer therapy, coupled with increasing awareness about cancer cure and treatment, are likely to drive the growth of the global cancer therapy market during the forecast period. Additionally, increasing Patient Assistance Programs (PAP’s), growing government initiatives for cancer awareness, and strong R&D Initiatives from key players are anticipated to drive the market for global cancer therapies.
The global cost of cancer therapy and drugs had increased from USD 91 billion to USD 113 billion in 2016.The US market is estimated to account for 46% of the global cancer cost. Factors, such as longer duration of cancer therapies, availability of novel agents, and use of combination therapy are contributing to the rising cost of cancer therapy. Additionally, cancer cost is expected to grow in the range of 6% to 9%, annually, during the forecast period. Thus, rising cost of cancer therapies, coupled with fluctuation of reimbursement policies for cancer treatment across the globe, is likely to impede the growth of the global cancer therapy market
North America dominates the global cancer therapy market, owing to high prevalence of cancer in the region because of a sedentary lifestyle, along with launch and growing adoption of novel cancer therapy in the region.
Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of cancer, growing awareness regarding cure and treatment of cancer, and increasing collaboration between public and private sectors to provide novel cancer therapy in the region.
Major Players: Amgen. AstraZeneca, Bristol-Meyrs Squibb Company, Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., Novartis AG, and Pfizer Inc., among others.